Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
Status:
Withdrawn
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the maximum tolerated dose and dose-limiting toxicities of
vemurafenib and/or cobimetinib when used with onartuzumab in cancer patients.